RAP-219 cut median clinical seizure frequency by 77.8% over eight weeks in a 30-patient Phase 2a study of drug‑resistant...

High-grade event-free survival in BCG-unresponsive papillary-only NMIBC reached 95.7%, 84.6%, and 80.4% at 3, 6, and 9 months, respectively,...

Mean absolute HbF rose 9.9% at Week 6 in the 20 mg cohort of Fulcrum’s Phase 1b PIONEER study,...

Relapse-free survival favored TSC-101 over standard transplant alone in the Phase 1 ALLOHA study with a hazard ratio of...

At the Veeva Clinical Oversight Forum, we spoke with Pinar Bénet, Senior Director of GTM Strategy and Clinical Lead...

In the non-pivotal, dose-confirmation stage of the randomized Phase 3 PRESERVE-003 trial in metastatic squamous NSCLC after PD-(L)1 therapy...

Topline data: In triple-class–exposed multiple myeloma patients with three prior lines of therapy from CARTITUDE-1, a single infusion of...

Preclinical data presented at ASH showed that Prelude Therapeutics’ JAK2V617F-selective JH2 inhibitor PRT12396 inhibited mutant JAK2 signaling while preserving...

In a 12-week, randomized, double-blind, placebo-controlled study in stable COPD, EP395 (glasmacinal) reduced sputum neutrophilic inflammation versus placebo, was...

In a Phase Ib/II study of 103 patients with myeloid malignancies, lisaftoclax plus azacitidine delivered an overall response rate...